PAVmed Inc (PAVMZ) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

PAVmed Inc (PAVMZ) Healthcare & Pipeline Overview

PAVmed Inc. is a U.S.-based medical device company specializing in minimally invasive surgical solutions and early cancer detection technologies. Its portfolio includes patented devices like CarpX for carpal tunnel syndrome and EsoCheck/EsoGuard for esophageal cancer screening, addressing significant unmet needs in diagnostic and therapeutic markets within the healthcare sector.

What Is the Investment Thesis for PAVMZ?

PAVmed Inc. operates within the dynamic medical device sector, focusing on innovative, minimally invasive solutions and early cancer detection. The company's investment thesis centers on the potential for its patented lead products, CarpX, EsoCheck, and EsoGuard, to gain market traction in their respective clinical areas. CarpX addresses the large market for carpal tunnel syndrome treatment with a minimally invasive approach, potentially reducing recovery times and improving patient experience. EsoCheck and EsoGuard target the critical need for early detection of esophageal adenocarcinoma and Barrett's Esophagus, conditions where early diagnosis significantly impacts prognosis. The company's pipeline, including EsoCure for dysplastic BE and PortIO for vascular access, suggests future growth avenues. However, the company currently faces significant financial challenges, evidenced by a profit margin of -21914.1% and a gross margin of -271.8%. These metrics indicate that PAVmed is in an early commercialization or development phase, requiring substantial investment without generating positive returns. The company's beta of 1.14 suggests higher volatility compared to the broader market. Future value drivers will depend on successful regulatory approvals, effective commercialization strategies, and market adoption of its innovative devices, alongside improved financial performance and pathway to profitability.

Based on FMP financials and quantitative analysis

PAVMZ Key Highlights

Market Capitalization: PAVmed Inc. currently holds a market capitalization of $0.00 billion, reflecting its early-stage commercialization or development phase within the medical device industry.

• Profitability Challenges: The company exhibits a significant profit margin of -21914.1%, indicating substantial operational losses relative to its revenue, typical for companies in intensive R&D and market entry phases.
• Gross Margin Deficit: PAVmed Inc. reports a gross margin of -271.8%, suggesting that the cost of goods sold significantly exceeds its revenue, highlighting challenges in product manufacturing efficiency or pricing strategy during its current stage.
• Market Volatility: With a Beta of 1.14, PAVmed Inc.'s stock demonstrates higher volatility compared to the overall market, implying greater sensitivity to market fluctuations.
• No Dividend Distribution: The company does not currently offer a dividend yield, which is common for growth-oriented medical device companies that typically reinvest earnings back into R&D and commercial expansion.

Who Are PAVMZ's Competitors?

PAVMZ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PAVMZ's Key Strengths?

Patented, innovative medical device portfolio addressing specific clinical needs.

• Focus on minimally invasive procedures and early disease detection, aligning with healthcare trends.
• Diverse product pipeline with potential future growth drivers across multiple therapeutic areas.
• Headquartered in New York City, providing access to a major biotech and financial hub.

What Are PAVMZ's Weaknesses?

Significant negative profit margin (-21914.1%) and gross margin (-271.8%), indicating lack of profitability.

• Small employee base (39 employees) for a company with a diverse pipeline, potentially limiting scale.
• Early-stage commercialization for several key products, requiring substantial ongoing investment.
• Reliance on successful regulatory approvals and market adoption for pipeline products.

What Could Drive PAVMZ Stock Higher?

PAVMZ catalyst: Potential regulatory approvals for pipeline products like EsoCure and PortIO, which could open new market segments for the company.

• Continued commercialization and market adoption of CarpX for carpal tunnel syndrome, driving revenue growth through increased procedural volume.
• Expansion of clinical utility and market penetration for EsoCheck and EsoGuard in early detection of esophageal adenocarcinoma and Barrett's Esophagus.
• Strategic partnerships or collaborations to accelerate the development and market entry of the Veris cancer care platform.

What Are the Key Risks for PAVMZ?

Financial-distress signal — its Altman Z-Score of -10.46 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-49.7%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Significant ongoing financial losses, as indicated by a profit margin of -21914.1% and gross margin of -271.8%, raising concerns about long-term financial sustainability without substantial revenue growth.
• Intense competition within the medical device sector from larger, more established companies with greater financial and marketing resources.
• Challenges in securing broad market adoption and favorable reimbursement for its innovative devices, which can hinder commercial success even after regulatory approval.
• The inherent risks associated with regulatory pathways for medical devices, including potential delays or failure to obtain necessary approvals for pipeline products.
• Dependence on successful execution of R&D and clinical trials for its extensive product pipeline, with potential for setbacks or increased costs.

What Are the Growth Opportunities for PAVMZ?

• Expansion of CarpX Market Penetration: CarpX, PAVmed's patented, single-use, minimally invasive surgical device for carpal tunnel syndrome, presents a significant growth opportunity. The global market for carpal tunnel release procedures is substantial, with millions of cases diagnosed annually. By offering a less invasive alternative to traditional open or endoscopic surgery, CarpX aims to reduce patient recovery times and potential complications, appealing to both patients and surgeons. Increased adoption through targeted marketing, physician training, and favorable reimbursement pathways could significantly expand its market share, particularly as healthcare systems increasingly prioritize outpatient and minimally invasive interventions. The timeline for this growth is ongoing, as commercialization efforts continue to scale.
• Commercialization of EsoCheck and EsoGuard for Early Cancer Detection: The EsoCheck esophageal cell collection device and the EsoGuard DNA assay represent a critical growth driver in the early detection of esophageal adenocarcinoma and Barrett's Esophagus. Esophageal cancer often has a poor prognosis due to late diagnosis, making early screening tools highly valuable. The market for early cancer diagnostics is expanding rapidly, driven by increased awareness and technological advancements. PAVmed's integrated solution offers a non-endoscopic, less invasive screening method, potentially broadening access to screening for at-risk populations. Successful clinical validation, favorable reimbursement, and widespread physician adoption could position these products as standard-of-care, tapping into a large, underserved diagnostic market over the next several years.
• Development and Launch of EsoCure for Dysplastic Barrett's Esophagus: PAVmed's pipeline includes EsoCure, an esophageal ablation device designed to treat dysplastic Barrett's Esophagus (BE), a precancerous condition. This device offers a therapeutic complement to EsoCheck and EsoGuard, creating a comprehensive solution from diagnosis to treatment. The market for treating dysplastic BE is significant, as effective ablation can prevent progression to esophageal cancer. Successful development, regulatory approval, and commercial launch of EsoCure would allow PAVmed to capture value across the entire patient journey for BE, enhancing its oncology portfolio. This opportunity is contingent on future regulatory milestones and is likely a mid-to-long-term growth driver, potentially within the next 3-5 years.
• Introduction of PortIO as an Intraosseous Vascular Access Device: PortIO, an implantable intraosseous vascular access device in PAVmed's pipeline, addresses a critical need for reliable vascular access, especially in patients where traditional venous access is challenging or impossible. This device could serve a broad patient population requiring long-term intravenous therapies, emergency access, or those with difficult venous anatomy. The market for vascular access devices is substantial and continuously evolving, driven by an increasing number of patients requiring chronic treatments. Successful development and regulatory clearance for PortIO would open a new revenue stream for PAVmed in a distinct medical device segment, offering a differentiated solution in a competitive market. This represents a potential growth opportunity in the medium term, subject to clinical trials and regulatory approvals.
• Leveraging the Veris Cancer Care Platform: The Veris cancer care platform, also in PAVmed's pipeline, signifies a strategic expansion into broader cancer management solutions. While specific details are not provided, a platform approach typically integrates diagnostics, treatment planning, and monitoring, aiming to provide a more holistic approach to cancer care. This could involve data analytics, personalized medicine tools, or integrated device management. The oncology market is one of the largest and fastest-growing segments in healthcare, driven by advancements in understanding and treating various cancers. A successful Veris platform could position PAVmed as a more comprehensive player in oncology, potentially creating significant value through recurring revenue models or integrated service offerings. This is a longer-term growth opportunity, likely requiring substantial R&D and strategic partnerships.

What Threats Does PAVMZ Face?

• Intense competition from established medical device companies with greater resources.
• Stringent and evolving regulatory approval processes for medical devices.
• Challenges in securing adequate reimbursement and market adoption for new technologies.
• Need for significant capital raises to fund ongoing R&D and commercialization efforts, leading to potential dilution.

What Are PAVMZ's Competitive Advantages?

• Patented Technology: PAVmed's lead products, including CarpX, EsoCheck, and EsoGuard, are patented, offering intellectual property protection and a competitive barrier against direct imitation.
• Minimally Invasive Focus: The company specializes in developing minimally invasive surgical and diagnostic devices, which often lead to better patient outcomes, faster recovery, and reduced healthcare costs compared to traditional methods.
• Early Detection Expertise: Its focus on early detection of serious conditions like esophageal adenocarcinoma and Barrett's Esophagus addresses a critical unmet need, providing a significant advantage in a market where early diagnosis is paramount.
• Diverse Product Pipeline: A robust pipeline spanning surgical, diagnostic, and therapeutic areas (e.g., EsoCure, PortIO, Veris platform) provides multiple potential future revenue streams and reduces reliance on a single product.

What Does PAVMZ Do?

PAVmed Inc., incorporated in 2014 and headquartered in New York City, New York, operates as a medical device company primarily within the United States. The company was initially known as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its core mission revolves around developing and commercializing innovative, minimally invasive medical technologies designed to address significant clinical needs across various therapeutic and diagnostic areas. PAVmed's product portfolio is anchored by several key offerings. CarpX stands out as a patented, single-use, disposable surgical device engineered for the minimally invasive treatment of carpal tunnel syndrome, aiming to provide a less arduous alternative to traditional surgical methods. In the realm of early cancer detection, the company offers EsoCheck, an esophageal cell collection device critical for the early identification of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Complementing EsoCheck is EsoGuard, a bisulfite-converted next-generation sequencing DNA assay, which further enhances the diagnostic capabilities for these conditions. Beyond its commercialized products, PAVmed maintains a robust product pipeline. This includes EsoCure, an esophageal ablation device intended for the treatment of dysplastic BE, representing a potential advancement in managing precancerous conditions. Another significant pipeline asset is PortIO, an implantable intraosseous vascular access device designed to offer an alternative for patients requiring long-term vascular access. The company's future innovations also encompass NextFlo and the Veris cancer care platform, indicating a strategic focus on expanding its presence in both diagnostic and interventional oncology. Through its diverse product offerings and pipeline, PAVmed Inc. positions itself as an innovator in the medical device landscape, targeting improvements in patient outcomes through advanced technological solutions.

What Products and Services Does PAVMZ Offer?

• Develops and commercializes patented medical devices for various clinical needs.
• Offers CarpX, a minimally invasive surgical device for carpal tunnel syndrome treatment.
• Provides EsoCheck, an esophageal cell collection device for early detection of Barrett's Esophagus and adenocarcinoma.
• Markets EsoGuard, a DNA assay for enhanced diagnostic capabilities in esophageal cancer screening.
• Is developing EsoCure, an esophageal ablation device for dysplastic Barrett's Esophagus.
• Has PortIO in its pipeline, an implantable intraosseous vascular access device.
• Is working on NextFlo and the Veris cancer care platform for future medical solutions.
• Focuses on single-use, disposable, and minimally invasive technologies.

How Does PAVMZ Make Money?

• Generates revenue from the sale of patented medical devices, such as CarpX.
• Monetizes diagnostic tools like EsoCheck and EsoGuard through sales to healthcare providers and laboratories.
• Focuses on single-use, disposable products, implying recurring revenue streams per procedure.
• Invests significantly in research and development to expand its product pipeline and secure future revenue streams.
• Aims to commercialize innovative devices that address unmet medical needs, seeking market adoption and reimbursement.

What Industry Does PAVMZ Operate In?

PAVmed Inc. operates within the highly specialized and competitive medical device industry, a sector characterized by continuous innovation, stringent regulatory oversight, and significant market potential. The company's focus on minimally invasive surgical devices, such as CarpX for carpal tunnel syndrome, aligns with a broader industry trend towards less invasive procedures that promise reduced patient recovery times and healthcare costs. Furthermore, its emphasis on early cancer detection technologies, including EsoCheck and EsoGuard for esophageal conditions, positions it within the growing market for diagnostic tools that improve patient outcomes through timely intervention. The medical device market is driven by an aging global population, increasing prevalence of chronic diseases, and technological advancements. PAVmed competes by offering patented solutions that aim to differentiate through clinical efficacy and procedural efficiency. The industry also faces pressures from healthcare cost containment initiatives and the need for robust clinical evidence, requiring companies like PAVmed to navigate complex market dynamics to secure adoption and reimbursement.

Who Are PAVMZ's Key Customers?

• Surgeons and orthopedic specialists performing carpal tunnel release procedures.
• Gastroenterologists and oncologists involved in esophageal disease diagnosis and treatment.
• Diagnostic laboratories and pathology centers utilizing advanced DNA assays.
• Hospitals and ambulatory surgical centers seeking minimally invasive and efficient medical technologies.
• Patients benefiting from less invasive procedures and earlier disease detection.

Company Profile

PAVmed Inc operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Lishan Aklog. PAVMZ has traded publicly since 2018.

Return on equity for PAVmed Inc stands at -49.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -41.0%, showing how much profit it generates from its asset base. A current ratio of 2.02 indicates the company holds enough short-term assets to cover its near-term obligations.

PAVMZ Valuation & Market Position

Relative to its peer group, PAVMZ's quantitative score of 53/100 is below the peer average of 65/100.

Quarterly Financial Performance: PAVmed Inc

Revenue for PAVmed Inc came in at $33K during Q2 2026, a 50.0% improvement versus the preceding quarter. The company recorded a net loss of $5.4M, with diluted EPS of $-0.87. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, PAVMZ averaged $-4.09 in diluted EPS.

PAVmed Inc's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -10.46 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project PAVmed Inc revenue of about $814K for fiscal 2026, with EPS near $0.00.

PAVMZ Financials

PAVMZ Latest News

No recent news available for PAVMZ.

PAVMZ Analyst Consensus

PAVMZ MoonshotScore

PAVMZ Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources